---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-052731"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:37:54.160075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q3 net loss $14M; cash $20.4M; Chairman exercises warrants for $10M

## Summary
- Net loss $14.0M ($0.24/sh) vs $8.6M ($0.14/sh) YoY; includes $3.6M non-cash deemed dividend from warrant modification.
- Cash and equivalents $20.4M at Sept 30; additional $30M available under chairman's credit line.
- Chairman Uihlein exercised 2.2M warrants at $4.49/sh for $10M gross proceeds; Dr. Benjamin Carson nominated to board.
- R&D expenses $7.7M (up from $6.6M) on hiring and belapectin activities; G&A $1.4M (down from $1.5M).
- Interim analysis for NAVIGATE belapectin trial on track for Q4 2023; company believes funded through Dec 2024.

## SEC filing metadata
- accession: 0001140361-23-052731
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/0001140361-23-052731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/ef20014482_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-052731
- JSON: https://secwatch.observer/filing/0001140361-23-052731.json
- Plain text: https://secwatch.observer/filing/0001140361-23-052731.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, EPS ($0.24) per share.
  - Period: the three months ended September 30, 2023
  - Net income: net loss applicable to common stockholders of $14.0 million, or ($0.24) per share
  - EPS: ($0.24) per share
  - Result: reported results
  source text: For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, compared to a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123052731/0001140361-23-052731-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.